Citi analyst David Lebowitz lowered the firm’s price target on BioMarin (BMRN) to $81 from $93 and keeps a Neutral rating on the shares. The company reported Q3 financial results, highlighting a top- and bottom-line beat and marginally raising fiscal 2024 guidance across all key metrics, the analyst tells investors in a research note. The firm says that Voxzogo came in shy of expectations, this was offset by better than expected results for several products in BioMarin’s enzyme replacement therapy business.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin price target lowered to $109 from $110 at JPMorgan
- William Blair downgrades BioMarin to Market Perform on lack of catalysts
- BioMarin downgraded to Market Perform from Outperform at William Blair
- BioMarin Reports Strong Q3 Growth and Positive Outlook
- BioMarin raises FY24 non-GAAP EPS view to $3.25-$3.35 from $3.10-$3.25